drugset / Trial / NCT04167163

Abaloparatide Before Total Knee Arthroplasty

NCT04167163

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss.

Timeline

Start
2020-01-10
Primary completion
2025-04-03
Completion
2025-04-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abaloparatide Peptide 80 ug Subcutaneous